A new mobility ecosystem will personalize every journey by 2030
Management and technology consultancy BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. The study, Mobility 2030, says all players will battle over customer and value chain data, and service offerings must address national as well as urban and rural demand patterns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005716/en/
BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. (Graphic: Business Wire)
“The automotive industry must respond to the human-centric mobility trend to stay ahead of the competition by maintaining its strategic position as the prime touchpoint to the customer. The industry must provide customers with truly personalized offerings, focus on collecting complex data to derive actionable insights, and orchestrate an ecosystem of partners that embraces new technologies,” said Dr. Stefan Penthin, Global Leader Automotive and Industrial Manufacturing at BearingPoint.
The study is the first in a series of three on mobility and drew from BearingPoint’s internal research, the views of clients across all industry segments and input from the consultancy’s segment and technology leaders. While the automotive industry is the focus, the study examines how all segments will be active in the new mobility ecosystem, from manufacturers and transportation providers to energy suppliers, government organizations, and insurance companies.
By 2030, the study projects that approximately 23% of all megacity trips will be through shared, on-demand mobility offerings (up from just 8% in 2021). By 2030, each player will be part of a demanding new infrastructure and alliance-ecosystem relationships that deliver multimodal journeys with diverse powertrains. Mobility will be consumed as a service, so access to data will be key. On-demand services mean all players will compete to acquire, analyze, and exploit customer data so they can react to changing travel patterns.
“In the journey to 2030, the transportation experience will become individualized, and new infrastructure, services, and relationships will be needed. Providers must be more user-centered and cater to rural and urban demands. Ultimately both utility companies and public transportation organizations will have a new and larger role,” said Marion Schulte, Global Leader Utilities, Postal and Transportation at BearingPoint.
Mobility that maximizes security, personal well-being, and sustainability
Various modes of travel will become integrated, enabling urban and rural intermodal transport hubs. Customers will demand mobility that maximizes security, personal well-being, and sustainability. Risk profiles will diverge for different usage and regions, the study foresees. According to EU statistics, 17 of the 20 busiest air routes in Europe cover distances of less than 434 miles, distances where intercity trains can offer faster, cleaner, and more sustainable journeys.
“As citizens demand greater availability, quality, and flexibility from mobility services, public transportation policy will evolve. Governments should ensure equal access to transport networks for all citizens, and the various modes of travel must be carefully integrated with safety, security, and personal well-being key priorities. Mobility policies should also be designed to maximize citizens productivity, both in terms of working and non-working time,” said Andrew Montgomery, Global Leader Government and Public Sector.
For more details and insights, you can download the study here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030-what-happens-when-every-journey-is-personalized/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005716/en/
Contact information
Press contact
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
